Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for presentation at the annual meeting of the American Society of Clinical Oncology.
Endeavor Health is studying Exact Sciences’ Cancerguard blood test to help see if multi-cancer detection should be deployed widely across hospitals. The five-year study aims to fill gaps in real-world evidence on how these tests perform and how they fit into routine healthcare.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Large numbers of men could have missed a prostate cancer diagnosis due to Covid-19. Combine that with a rise in prostate cancer and the future looks grim. Ultimately, something in the prostate cancer diagnostic landscape needs to change: but what?
Providence recently launched a study to help learn more about how health systems can use multi-cancer detection tests in clinical care. Three years ago, Providence became the first health system to use Grail’s Galleri test, which screens patients for more than 50 kinds of cancer.